Back to Journals » International Journal of Nanomedicine » Volume 17

Macroporous Nanofibrous Vascular Scaffold with Improved Biodegradability and Smooth Muscle Cells Infiltration Prepared by Dual Phase Separation Technique [Corrigendum]

Authors Wang W, Nie W, Liu D, Du H, Zhou X, Chen L, Wang H, Mo X , Li L, He C 

Received 19 September 2022

Accepted for publication 19 September 2022

Published 4 October 2022 Volume 2022:17 Pages 4697—4698


Wang W, Nie W, Liu D, et al. Int J Nanomedicine. 2018;13:7003–7018.

The authors have advised the representative image of the migratory HVSMCs for the TCP (Figure 13A) and PLLA/PLGA/PCL scaffold (Figure 13B) on Page 7017 were overlapped. Following a review of the original images, the authors found different sets of images were mixed when processing the data which resulted in the incorrect image to be used for PLLA/PLGA/PCL (Figure 13B).

The correct Figure 13 is shown below.

Figure 13 (AD) The representative image of the migratory HVSMCs located on the lower site of Transwell membrane for the TCP, PLLA/PLGA/PCL, PLLA/PLGA/PCL-Heparin, and PLLA/PLGA/PCL-PDGF-BB scaffolds, respectively. (E) The quantification of HVSMCs migration.

Abbreviations: HVSMCs, human vascular smooth muscle cells; PCL, poly(ε-caprolactone); PDGF-BB, platelet-derived growth factor-BB; PLGA, poly(lactic-co-glycolic acid); PLLA, poly(L-lactic acid); TCP, tissue culture plate.

Notes: *PP<0.01.

The authors apologize for this error and advise it does not affect the results and conclusions of the paper.

Read the original article

Creative Commons License © 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.